SpyGlass Pharma

SpyGlass Pharma was founded in 2019 by Dr. Malik Y. Kahook, MD and Glenn Sussman to redefine the treatment of chronic ophthalmic diseases through sustained drug delivery. Based in Aliso Viejo, California, the company is focused on developing innovative solutions for patients suffering from chronic eye conditions, particularly glaucoma and cataracts. With over 15 years of partnership between its founders, SpyGlass combines complementary expertise from ophthalmic surgery, medical device engineering, and product development to address significant unmet needs in eye care. The company's lead product, the SpyGlass BIM-IOL System, integrates long-acting glaucoma medication delivery into an intraocular lens (IOL) implanted during routine cataract surgery. This novel approach enables sustained drug release over multiple years while restoring clear vision, potentially treating millions of patients with both conditions in a single procedure. SpyGlass Pharma is advancing through Phase 3 clinical trials and has secured significant funding, including a $75 million Series D financing round, demonstrating strong investor confidence in their drug delivery platform technology.